Companies / United Arab Emirates
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Julphar Boosts Full-Year Sales, But Q4 Dips
September 2006 | Company Finance AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
UAE-based drugmaker Julphar has recorded sales of AED641mn (US$174.52mn) for the financial year 2005/2006, a 17% increase on the previous year. Strong sales in the private sector, which swelled by 35% in the reporting period, have driven this positive performance. According to company sources, this points to a growing acceptance of Julphar's products among specialists as well as patients. Thirty, out of the company's 480 products are reported to have registered 'phenomenal' sales.